File No: LTD/1416

October 2009

NATIONAL INDUSTRIAL CHEMICALS NOTIFICATION AND ASSESSMENT SCHEME (NICNAS)

FULL PUBLIC REPORT

CIM-10

This Assessment has been compiled in accordance with the provisions of the *Industrial Chemicals (Notification and Assessment) Act 1989* (Cwlth) (the Act) and Regulations. This legislation is an Act of the Commonwealth of Australia. The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is administered by the Department of Health and Ageing, and conducts the risk assessment for public health and occupational health and safety. The assessment of environmental risk is conducted by the Department of the Environment, Water, Heritage and the Arts.

For the purposes of subsection 78(1) of the Act, this Full Public Report may be inspected at our NICNAS office by appointment only at 334-336 Illawarra Road, Marrickville NSW 2204.

This Full Public Report is also available for viewing and downloading from the NICNAS website or available on request, free of charge, by contacting NICNAS. For requests and enquiries please contact the NICNAS Administration Coordinator at:

| 334 - 336 Illawarra Road MARRICKVILLE NSW 2204, AUSTRALIA. |
|--|
| GPO Box 58, SYDNEY NSW 2001, AUSTRALIA. |
| + 61 2 8577 8800 |
| + 61 2 8577 8888 |
| www.nicnas.gov.au |
| |

Director NICNAS

TABLE OF CONTENTS

| FULL PUBLIC RE | PORT | 3 |
|----------------------|--|----|
| 1. APPLI | CANT AND NOTIFICATION DETAILS | 3 |
| 2. IDENT | TITY OF CHEMICAL | 3 |
| | OSITION | |
| 4. PHYSI | ICAL AND CHEMICAL PROPERTIES | 3 |
| | DUCTION AND USE INFORMATION | |
| | AN HEALTH IMPLICATIONS | |
| | Exposure assessment | |
| 6.1.1 | | |
| 6.1.2. | 1 | |
| | Human health effects assessment. | |
| | Iuman health risk characterisation | |
| 6.3.1. | 1 2 | |
| 6.3.2. | | |
| | RONMENTAL IMPLICATIONS | |
| | Environmental Exposure & Fate Assessment | |
| 7.1.1 | Environmental Exposure | |
| 7.1.2 | Environmental fate | |
| 7.1.3 | Predicted Environmental Concentration (PEC) | |
| | Environmental effects assessment | |
| 7.2.1 | Predicted No-Effect Concentration | |
| | Environmental risk assessment | |
| | LUSIONS AND REGULATORY OBLIGATIONS | |
| | IVSICAL AND CHEMICAL PROPERTIES | |
| | XICOLOGICAL INVESTIGATIONS | |
| | Acute toxicity – oral | |
| | Acute toxicity – dermal. | |
| | rritation – skin | |
| | rritation – eye | |
| | Skin sensitisation – mouse local lymph node assay (LLNA) | |
| | Repeat dose toxicity Genotoxicity – bacteria | |
| | Genotoxicity – bacteria | |
| | Genotoxicity – bacteria | |
| | VIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS | |
| | Environmental Fate | |
| C.1. 1 C.1.1. | Ready biodegradability | |
| C.1.2. | | |
| | Ecotoxicological Investigations | |
| C.2.1. | | 21 |
| C.2.2. | Acute toxicity to aquatic invertebrates | |
| C.2.2. C.2.3. | Acute to Acute to Aquate invertebrates | |
| C.2.4. | Lemna growth inhibition test. | |
| C.2.5. | Inhibition of microbial activity | |
| | | |
| DIDEROOICHTIT | | 20 |

FULL PUBLIC REPORT

CIM-10

1. APPLICANT AND NOTIFICATION DETAILS

APPLICANT(S) Canon Australia Pty Ltd (ABN: 66 005 002 951) 1 Thomas Holt Drive North Ryde NSW 2113

NOTIFICATION CATEGORY Limited-small volume: Chemical other than polymer (1 tonne or less per year).

EXEMPT INFORMATION (SECTION 75 OF THE ACT) Data items and details claimed exempt from publication: Chemical Name, Other Names, CAS Number, Molecular and Structural Formulae, Spectral Data, Molecular Weight, Purity, Impurities, Import Volume, Use Details.

VARIATION OF DATA REQUIREMENTS (SECTION 24 OF THE ACT) No variation to the schedule of data requirements is claimed.

 $\begin{array}{l} \mbox{Previous Notification in Australia by Applicant(s)} \\ \mbox{LVC}/742 \end{array}$

NOTIFICATION IN OTHER COUNTRIES USA (2007); UK (2007); Switzerland (2008); Japan (2008); Korea (2008); Philippines (2008)

2. IDENTITY OF CHEMICAL

MARKETING NAME(S) CIM-10 Black C-BK4 Liq. Black C-BK4 C-BK4

MOLECULAR WEIGHT >1000 Da

ANALYTICAL DATA Reference NMR, IR, HPLC, LC/MS, UV/vis spectra were provided.

3. COMPOSITION

DEGREE OF PURITY >85%

ADDITIVES/ADJUVANTS None

4. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE AT 20°C AND 101.3 kPa: Black powder

| Property | Value | Data Source/Justification |
|------------------------------|------------------------|---------------------------|
| Melting Point/Freezing Point | Decomposed from ~322°C | Measured |

| Boiling Point Density Vapour Pressure Water Solubility | Not determined 1630 kg/m ³ at 19.5 ± 0.5°C < 2 x 10 ⁻⁸ kPa at 25°C 350-360 g/L at 20°C | Decomposed prior to melting Measured Measured Measured |
|---|---|---|
| Hydrolysis as a Function of pH | Stable (half-life > 1 year at pH 4, 7 and 9) | Measured |
| Partition Coefficient (n-octanol/water) | $\log P_{ow} = -4.88 \text{ at } 21^{\circ} \text{C}$ | Measured |
| Surface Tension | 71.9 mN/m (1 g/L solution) at 21.8 $\pm 0.2^{\circ}$ C | Measured |
| Adsorption/Desorption | $\log K_{oc} < 1.25$ at 40°C | Measured |
| Dissociation Constant | $pKa = 6.35, 2.22, 1.62, \le -0.71$ | Calculated |
| Particle Size | Inhalable fraction (<100 μ m): 32.3% | Measured |
| | Respirable fraction (<10 μm): 1.14% | |
| Flash Point | Not determined | Low vapour pressure solid |
| Solid Flammability | Not highly flammable | Measured |
| Autoignition Temperature | Does not self-ignite below 400°C | Measured |
| Explosive Properties | Not explosive | Measured |
| Oxidising Properties | Not expected to be oxidising | Estimated |

DISCUSSION OF PROPERTIES

For full details of tests on physical and chemical properties, please refer to Appendix A.

Reactivity

The notified chemical is not expected to be reactive under normal conditions of use.

5. INTRODUCTION AND USE INFORMATION

MODE OF INTRODUCTION OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS The notified chemical will be imported as a component (<5%) of inkjet printer ink contained within sealed ink cartridges.

MAXIMUM INTRODUCTION VOLUME OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS

| Year | 1 | 2 | 3 | 4 | 5 |
|--------|----|----|----|----|----|
| Tonnes | <1 | <1 | <1 | <1 | <1 |

PORT OF ENTRY Sydney

IDENTITY OF MANUFACTURER/RECIPIENTS

Canon Australia Pty Ltd and office equipment retailers and offices nationwide.

TRANSPORTATION AND PACKAGING

Imported ink cartridges (5 mL - 900 mL) containing the notified chemical (each individually sealed in a plastic bag and packaged in a box) will be stored at the notifier's warehouse prior to distribution to offices and office equipment retailers nationwide.

USE

The notified chemical will be used as a component (<5%) in ink cartridges for use in inkjet printers.

OPERATION DESCRIPTION

No manufacture or reformulation will occur in Australia. Sealed ink cartridges containing the notified chemical will be distributed to commercial and retail centres and handled by service technicians, office workers or the public, who will replace spent cartridges in printers as necessary.

6. HUMAN HEALTH IMPLICATIONS

6.1 Exposure assessment

6.1.1 Occupational exposure

NUMBER AND CATEGORY OF WORKERS

| Category of Worker | Number | Exposure Duration (hours/day) | Exposure Frequency (days/year) |
|-------------------------|-----------|----------------------------------|-----------------------------------|
| Importation/Waterside | 50 | <8 | 10-50 |
| Storage and Transport | 15 | <8 | 10-50 |
| Office worker/ consumer | 2,000,000 | 10 seconds/day | 2 |
| Service Technicians | 100 | 1 | 170 |

EXPOSURE DETAILS

Storage and transport workers will only handle the sealed cartridges containing the notified chemical and therefore exposure is not expected unless the packaging is accidentally breached.

Service technicians and office workers may be exposed to the ink containing the notified chemical (<5%) when replacing used ink cartridges and repairing and cleaning ink jet printers. Dermal exposure is expected to be the most likely route of exposure. However, occasional dermal exposure during use of the printer may occur if the printed pages were handled inadvertently before the ink had dried, or if ink-stained parts of the printer were touched. Once the ink dries, the chemical would be bonded to the printed paper, and therefore dermal exposure to the notified chemical from contact with dried ink is not expected.

6.1.2. Public exposure

Home users may encounter dermal exposure to the ink containing the notified chemical (<5%) when replacing used ink cartridges similar to the exposure experienced by office workers. However, home users are expected to handle ink cartridges and print less frequently, therefore exposure is expected to be less frequent when compared to that of office workers.

6.2. Human health effects assessment

The results from toxicological investigations conducted on the notified chemical are summarised in the table below. Details of these studies can be found in Appendix B.

| Endpoint | Result and Assessment Conclusion |
|---|---|
| Rat, acute oral toxicity | low oral toxicity LD50 >2000 mg/kg bw |
| Rat, acute dermal toxicity | low dermal toxicity LD50 >2000 mg/kg bw |
| Rabbit, skin irritation | non-irritating |
| Rabbit, eye irritation | slightly irritating |
| Mouse, skin sensitisation – Local lymph node assay | no evidence of sensitisation |
| Rat, repeat dose oral toxicity – 28 days. | NOEL 1000 mg/kg bw/day |
| Mutagenicity – bacterial reverse mutation | non mutagenic |
| Mutagenicity – bacterial reverse mutation | non mutagenic |
| (incorporating Prival and Mitchell modification for | |
| azo colourants) | |
| Genotoxicity - in vitro chromosome aberration | non genotoxic |

Toxicokinetics, metabolism and distribution

Many azo dyes are unlikely to be absorbed through the skin because of their size and polarity (Øllgaard, 1998). Smaller species may undergo percutaneous absorption, dependent on their properties. There was no evidence from the toxicological investigations to suggest that the notified chemical was absorbed following dermal exposure. Absorption through the skin is not expected to be significant, given its relatively high molecular weight (>500 Da), high water solubility (>10 g/L), and low partition coefficient (log P < 0). These parameters demonstrate its low lipophilicity, indicating that it is not likely to cross the stratum corneum (European Commission, 2003). However, bacterial skin microflora have been reported to be able to break down azo dyes into smaller species, which may be more readily absorbed, through azo reduction (SCCNFP, 2002).

Highly sulfonated azo dyes are generally poorly absorbed from the intestine after oral intake. However, cleavage of the azo linkage may take place in the gastrointestinal tract, through the action of azo reductases (see below). The sulfonated aromatic amines are rapidly absorbed. Given the black or brown/purple coloured urine observed in animals during the oral studies, the observed blue contents of the gastrointestinal tract and discolouration of organs in the repeat dose oral toxicity study, it is clear that the notified chemical can be absorbed, perhaps following reduction, from the gastrointestinal tract after oral exposure.

Ultimately, the metabolites of azo dyes are expected to be excreted in the urine and bile (Brown & DeVito, 1993, referenced in Øllgaard, 1998). Sulfonation of azo dyes appears to decrease their toxicity by enhancing their urinary excretion, and that of their metabolites. The coloured urine observed in many animals that had been orally administered with the notified chemical could be indicative of the urinary excretion of metabolites of the notified chemical.

A significant proportion of the notified chemical (32.3%) is of inhalable particle size (<100 μ m) and only a small fraction (1.14%) is of respirable size (<10 μ m). The particles of inhalable size are expected to diffuse or dissolve into the mucus lining of the respiratory tract and be retained in the mucus and then transported out of the respiratory tract.

Acute toxicity

The notified chemical was found to be of low acute oral and dermal toxicity in studies conducted on rats (LD50 > 2,000 mg/kg bw). No information on the acute inhalation toxicity was available.

Irritation and Sensitisation

The notified chemical was found to be slightly irritating to the eye, though not enough to warrant hazard classification, and non-irritating to the skin.

The notified chemical was not a skin sensitiser when tested in a mouse local lymph node assay up to a concentration of 25% (maximum concentration that could technically be applied). Therefore, the notified chemical is unlikely to cause skin sensitisation in exposed humans.

Repeat dose toxicity

The NOEL in a 28-day oral repeat dose study in rats was established as the highest dose (1000 mg/kg bw/day), based on the absence of toxicologically significant changes in the parameters measured at all dose levels. Hence, the NOAEL is considered as \geq 1000 mg/kg bw/day.

Mutagenicity and Carcinogenicity

Azo dyes are a concern for their potential induction of mutagenicity and carcinogenicity, mainly through their reduction to aromatic amines in the body. Exposure to heat or sunlight has also been reported to result in breakdown of azo dyes, including some that are similar to the notified chemical (Brown and DeVito, 1993).

The notified chemical is not expected to be reductively cleaved to release any of the restricted aromatic amines specified in either the Appendix to EC Directive 76/769/EEC (EC, 2004) or the annexes of EU SCCNFP/0495/01 (SCCNFP, 2002). However, it may be degraded to form species that resemble these arylamines, some of which are suspected of being mutagenic. However, due to their significant structural modification and the suggestive negative test data of these species, the amine species may not exhibit mutagenicity.

In addition, azo dyes are known for their content of impurities, particularly for the presence of component arylamines (SCCNFP, 2002; Øllgaard *et al* 1998). The HPLC trace provided by the notifier indicates that the sample of the notified chemical contains a number of impurities that have not been identified, each present at <1%. These impurities are both more and less polar than the notified chemical and are likely to be free amine species and/or sulfonation variants. Free amines may exhibit higher toxicity than the notified chemical as they are likely to be more readily absorbed across the skin.

The notifier supplied test results showing that the notified chemical was found to be not mutagenic in bacteria (under the conditions of the Ames test used), and did not induce chromosomal aberrations in mammalian cells *in vitro*. Furthermore, the notifier also supplied a summary of test results from a study showing that the notified chemical was found to be not mutagenic using the modified Ames test for azo dyes (Prival and Mitchell, 1982). This modified test is thought to yield a greater detection of mutagenic azo dyes as it utilises a reductive pre-

incubation step (during which the azo dye is reduced to amine species) before the test is carried out.

Overall, on the basis of weight of evidence the notified chemical is not expected to be genotoxic.

Health hazard classification

Based on the available data the notified chemical is not classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances* (NOHSC, 2004).

6.3. Human health risk characterisation

6.3.1. Occupational health and safety

Based on the data supplied, the notified chemical has no identified hazards. Dermal exposure of workers to the notified chemical should occur infrequently and be of small amounts, given the containment of the notified chemical within ink cartridges.

The level of repeat dermal exposure for service technicians and office workers handling sealed cartridges of printing inks containing the notified chemical at < 5% is not expected to be significant compared to the NOEL of 1000 mg/kg bw/day established in the 28 day rat study.

Overall, the risk presented by the notified chemical to the health and safety of workers is not considered to be unacceptable.

6.3.2. Public health

The exposure and hazard of the notified chemical to the members of the public during the use of inkjet printers are expected to be identical or similar to that experienced by office workers. Therefore, the risk of the notified chemical to the health of the public is not considered to be unacceptable.

7. ENVIRONMENTAL IMPLICATIONS

7.1. Environmental Exposure & Fate Assessment

7.1.1 Environmental Exposure

RELEASE OF CHEMICAL AT SITE

The notified chemical will be imported to Australia as a component of printer ink final product in ready-to-use cartridges. No manufacturing and reformulation of the notified chemical will take place in Australia. Environmental release of the notified chemical is unlikely to occur during importation, storage and transportation.

RELEASE OF CHEMICAL FROM USE

The ink cartridges will be designed to prevent leakage and will not be opened during transport, use, installation or replacement. Therefore, release of ink containing the notified chemical to the environment is not expected under normal conditions of use. Workers at large businesses will undertake installation and replacement. If leakage or spillage does occur, the ink will be contained with absorbent material and disposed of to landfill in accordance with federal, state and local regulations.

Cartridges will be contained within the printer until the contents are consumed and then they will be removed and sent for recycling or disposed of to landfill. Around 5% of the ink containing the notified chemical will remain in "empty" cartridges.

Most of the notified chemical (95%) will be bound to printed paper, which will be disposed of to landfill, recycled or possibly incinerated.

RELEASE OF CHEMICAL FROM DISPOSAL

Around 5 wt% of the ink containing the notified chemical will remain in "empty" cartridges. The notifier will collect the used cartridges by setting up the collection boxes in general merchandising stores and post offices, etc. The collected cartridges will be sent to a subcontractor. The subcontractor will disassemble the used cartridges and recycle them as raw materials, for example, to be used to make plastic goods. The remaining ink separated from the used cartridges will be disposed of under Australian regulations. The notifier will not refill

the used cartridges for reuse. The other cartridges which are not collected will be disposed of to landfill.

Printed paper, having the notified chemical thereon will be disposed of to landfill, recycled or possibly incinerated. Recycling of treated paper may result in the release of a proportion of the notified chemical to the aquatic compartment. Waste paper is re-pulped using a variety of chemical treatments, which result in fibre separation and ink detachment from the fibres. The wastes are expected to go to trade waste sewers. Approximately 50% of the ink printed on paper will enter paper recycling and a minor proportion of the ink may be recovered during recycling in the sludge. Any quantities of notified chemical recovered with sludge during the recycling process will be disposed of to landfill.

7.1.2 Environmental fate

The notified chemical is water soluble and not readily biodegradable, and could therefore be expected to pass through sewage treatment works and disperse in receiving waters. In practice, the notified chemical can be expected to precipitate during sewage treatment and in surface waters as sparingly soluble calcium salts. Bioaccumulation is not expected as the notified chemical has high molecular weight and is water soluble. For details of the environmental fate studies please refer to Appendix C.

7.1.3 Predicted Environmental Concentration (PEC)

The PEC is estimated below based on the assumption that 50% of the imported quantity will enter paper recycling streams and be discharged in aqueous effluent following detachment from the fibre. Note that the assumption of complete release to surface water is highly conservative as the notified chemical is expected to precipitate as calcium salts.

| Predicted Environmental Concentration (PEC) for the Aquatic Compartment | | |
|---|---------|--------------|
| Total Annual Import/Manufactured Volume | < 1000 | kg/year |
| Proportion expected to be released to sewer | 0.5 | |
| Annual quantity of chemical released to sewer | < 500 | kg/year |
| Days per year where release occurs | 365 | days/year |
| Daily chemical release: | < 1.37 | kg/day |
| Water use | 200.0 | L/person/day |
| Population of Australia (Millions) | 21.374 | million |
| Removal within STP | 0% | |
| Daily effluent production: | 4,275 | ML |
| Dilution Factor - River | 1.0 | |
| Dilution Factor - Ocean | 10.0 | |
| PEC - River: | < 0.32 | μg/L |
| PEC - Ocean: | < 0.032 | µg/L |

7.2. Environmental effects assessment

The results from ecotoxicological investigations conducted on the notified chemical are summarised in the table below. Details of these studies can be found in Appendix C.

| Endpoint | Result | Assessment Conclusion |
|-------------------------------------|------------------------------|-----------------------|
| Fish Toxicity | LC50 > 100 mg/L | Not harmful |
| Daphnia Toxicity | EC50 > 100 mg/L | Not harmful |
| Algal Toxicity | $E_r C50 > 100 \text{ mg/L}$ | Not harmful |
| Lemna Toxicity | EC50 > 100 mg/L | Not harmful |
| Inhibition of Bacterial Respiration | EC50 > 1000 mg/L | Not harmful |

The results from testing indicate that the notifed chemical is not harmful to aquatic life, consistent with its water solubility. The algal test was discontinued in favour of the Lemna test because of indications that algal growth was inhibited by light absorption.

7.2.1 Predicted No-Effect Concentration

The PNEC can be estimated as outlined below by application of a 100-fold assessment factor, as data are available for three trophic levels.

| Predicted No-Effect Concentration (PNEC) for the Aquatic Compartment | | | |
|--|--------|------|--|
| Aquatic toxicity | > 100 | mg/L | |
| Assessment Factor | 100 | | |
| PNEC: | > 1000 | µg/L | |

7.3. Environmental risk assessment

The Risk Quotients (Q = PEC/PNEC) are tabulated below.

| Risk Assessment | PEC µg/L | PNEC µg/L | Q |
|-----------------|----------|-----------|------------|
| Q - River | 0.32 | > 1000 | < 0.00032 |
| Q - Ocean | 0.032 | > 1000 | < 0.000032 |

The notified chemical is not considered to pose a risk to the environment as risk quotients are well below one, even under the hypothetical worst case assumption that the notified chemical will be discharged to surface waters after detachment from paper fibres during recycling.

8. CONCLUSIONS AND REGULATORY OBLIGATIONS

Hazard classification

Based on the available data the notified chemical is not classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances* [NOHSC:1008(2004)].

Human health risk assessment

Under the conditions of the occupational settings described, the notified chemical is not considered to pose an unacceptable risk to the health of workers.

When used in the proposed manner, the notified chemical is not considered to pose an unacceptable risk to public health.

Environmental risk assessment

On the basis of the PEC/PNEC ratio and the reported use pattern, the notified chemical is not considered to pose a risk to the environment.

Recommendations

CONTROL MEASURES Occupational Health and Safety

• No specific engineering controls, work practices or personal protective equipment are required for the safe use of the notified chemical itself, however, these should be selected on the basis of all ingredients in the formulation.

Guidance in selection of personal protective equipment can be obtained from Australian, Australian/New Zealand or other approved standards.

- A copy of the MSDS should be easily accessible to employees.
- If products and mixtures containing the notified chemical are classified as hazardous to health in accordance with the *Approved Criteria for Classifying Hazardous Substances* [NOHSC:1008(2004)]

workplace practices and control procedures consistent with provisions of State and Territory hazardous substances legislation must be in operation.

Disposal

• The notified chemical should be disposed of to landfill.

Emergency procedures

• Spills or accidental release of the notified chemical should be handled by physical containment, collection and subsequent safe disposal.

Regulatory Obligations

Secondary Notification

This risk assessment is based on the information available at the time of notification. The Director may call for the reassessment of the chemical under secondary notification provisions based on changes in certain circumstances. Under Section 64 of the *Industrial Chemicals (Notification and Assessment) Act (1989)* the notifier, as well as any other importer or manufacturer of the notified chemical, have post-assessment regulatory obligations to notify NICNAS when any of these circumstances change. These obligations apply even when the notified chemical is listed on the Australian Inventory of Chemical Substances (AICS).

Therefore, the Director of NICNAS must be notified in writing within 28 days by the notifier, other importer or manufacturer:

- (1) Under Section 64(1) of the Act; if
 - the importation volume exceeds one tonne per annum notified chemical;
- (2) Under Section 64(2) of the Act; if
 - the function or use of the chemical has changed from a component of inkjet printer ink, or is likely to change significantly;
 - the amount of chemical being introduced has increased from one tonne per annum, or is likely to increase, significantly;
 - the chemical has begun to be manufactured in Australia;
 - additional information has become available to the person as to an adverse effect of the chemical on occupational health and safety, public health, or the environment.

The Director will then decide whether a reassessment (i.e. a secondary notification and assessment) is required.

Material Safety Data Sheet

The MSDS of products containing the notified chemical provided by the notifier was reviewed by NICNAS. The accuracy of the information on the MSDS remains the responsibility of the applicant.

| October 2009 | | | NICNAS |
|--------------------------|---|--|---|
| | Appendix | A: Physical and Chemicai | L PROPERTIES |
| Melting Point/Fr | eezing Point | Decomposed from approxima | tely 322 °C |
| Method | | Melting Point/Melting Range. | |
| Remarks Test Facility | | 2/69/EEC A.1 Melting/Freezing Ter nning calorimetry. 7a) | nperature. |
| Boiling Point | | Not determined | |
| Remarks | | nperature was not determined as r to melting (see above). | the notified chemical was found to |
| Test Facility | SafePharm (200 | | |
| Density | | 1630 kg/m ³ at 19.5 \pm 0.5°C | |
| Method | | Density of Liquids and Solids. /69/EEC A.3 Relative Density. | |
| Remarks Test Facility | Gas comparison SafePharm (200 | pycnometer. | |
| Vapour Pressure | | $< 2 \ x \ 10^{\text{-8}} \ \text{kPa}$ at 25°C | |
| Method | | Vapour Pressure. /69/EEC A.4 Vapour Pressure. | |
| Remarks | Determined usir thus statistical a | ng a vapour pressure balance. Balan nalysis was not meaningful. A reg | nce readings were low and variable and ression slope was imposed on a chosen value for the vapour pressure at 25°C. |
| Test Facility | SafePharm (200 | | and for the vapour pressure at 25°C. |
| Water Solubility | | 350-360 g/L at 20°C | |
| Method | | Water Solubility. /69/FEC A 6 Water Solubility | |
| Remarks | EC Directive 92/69/EEC A.6 Water Solubility. Flask Method. The solubility was estimated by visual inspection because of difficulties with filtration at concentrations near the solubility limit. | | |
| Test Facility | SafePharm (200 | | mm. |
| Hydrolysis as a F | unction of pH | Half-life at $25^{\circ}C > 1$ year at p | H 4, 7 and 9 |
| Method | | Hydrolysis as a Function of pH. //69/EEC C.7 Degradation: Abiotic | Degradation: Hydrolysis as a Function |
| p | Н | $T(\mathcal{C})$ | $t_{1/2}$ |

| pН | $T(\mathcal{C})$ | $t_{1/2}$ |
|----|------------------|-------------|
| 4 | 50 | > 120 hours |
| 7 | 50 | > 120 hours |
| 9 | 50 | 415 hours |

At pH4 and pH 7, less than 10% hydrolysis was detected after 5 days, which is equivalent Remarks to a half-life greater than 1 year at 25°C. At pH 9, the half-life at 25°C is estimated greater than 1 year under Arrhenius plot at 50°C, 60°C and 70°C. Half-lives at pH 9 reduced to 55.8 hours at 60° C and 7.1 hours at 70° C. SafePharm (2007b)

Test Facility

| Partition Coefficient (n- |
|---------------------------|
| octanol/water) |

 $\log Pow = -4.88$ at $21^{\circ}C$

| Method | OECD TG 107 Pa | rtition Coefficient (n-octanol/water). | | | |
|----------------------------------|--|---|--|--|--|
| | EC Directive 92/69/EEC A.8 Partition Coefficient. | | | | |
| Remarks | Flask Method with analysis by HPLC. A preliminary estimate of < -4.33 was obtained | | | | |
| | from the approximate solubilities in n-octanol ($< 8 \text{ mg/L}$) and water ($> 171 \text{ g/L}$). | | | | |
| Test Facility | SafePharm (2007a | | | | |
| Surface Tension | | 71.9 mN/m at $21.8 \pm 0.2^{\circ}$ C | | | |
| Method | | 9/EEC A.5 Surface Tension. | | | |
| | | balance and procedure based on the ISO 304 ring method. | | | |
| Remarks | Concentration: 0.9 | | | | |
| Test Feeility | | be a surface active material. | | | |
| Test Facility | SafePharm (2008a | () | | | |
| Adsorption/Deso – screening test | rption | $\log K_{oc} < 1.25$ at 40°C | | | |
| Method | OECD TG 121 Es Using HPLC. | stimation of the Adsorption Coefficient on Soil and on Sewage Sludge | | | |
| Remarks | U | eluted from the column before the reference substance acetanilide. | | | |
| Test Facility | SafePharm (2007b | | | | |
| Dissociation Con | stant | $pKa_1 = 6.35, pKa_2 = 2.22, pKa_{3\text{-}4} = 1.62, pKa_{5\text{-}7} \le \text{-}0.71,$ | | | |
| Method | OECD TG 112 Di | ssociation Constants in Water. | | | |
| Remarks | | constants were estimated (ACD/pKa 8.03) as there was no pKa within | | | |
| | | ne spectrometric and titrimetric test methods. The notified chemical is a | | | |
| | | that is expected to be ionised in the environment. | | | |
| Test Facility | SafePharm (2007b | | | | |
| Particle Size | | | | | |
| Method | OECD TG 110 Pa | rticle Size Distribution/Fibre Length and Diameter Distributions. | | | |
| | Range (µm) | Mass (%) | | | |
| | <100 | 32.3 | | | |
| | <10.0 | 1.14 | | | |
| | <5.5 | 0.141 | | | |
| Remarks | The fraction <100 | μ m was determined by passing through a sieve. The fraction <10 μ m | | | |
| Kennarks | | using a cascade impactor, with results averaged from three separate | | | |
| | determinations. | sing a cascade implactor, while results averaged from three separate | | | |
| | | were of size $<10 \ \mu m$ to allow accurate determination of the mass | | | |
| | median aerodynam | | | | |
| Test Facility | SafePharm (2007b | | | | |
| Solid Flammabili | ity | Not highly flammable | | | |
| Method | EC Directive 92/6 | 9/EEC A.10 Flammability (Solids). | | | |
| Test Facility | SafePharm (2007d | • • • | | | |
| Autoignition Ten | | Does not self-ignite below 400°C | | | |
| 0 | - | | | | |
| Method | | 9/EEC A.16 Relative Self-Ignition Temperature for Solids. | | | |
| Kemarks | Remarks The notified chemical decomposed during the test. | | | | |
| Test Facility | SafePharm (2007c | | | | |

Explosive Properties Not explosive

| Method | EC Directive 92/69/EEC A.14 Explosive Properties. |
|---------------|--|
| Remarks | The notified chemical is not considered to be explosive as it was not thermally sensitive, |
| | shock sensitive or friction sensitive. |
| | Note that during the thermal sensitivity test performed with the 2mm orifice plate, explosions were observed at approximately 80 seconds into each of the three individual |
| | tests. In each case there was damage to the tube, however, it did not fragment into three |
| | or more pieces and thus according to the test guideline, the notified chemical is not considered to be explosive. |
| | 1 |
| Test Facility | SafePharm (2007c) |

Oxidizing Properties

| Method | EC Directive 92/69/EEC A.17 Oxidizing Properties (Solids). |
|---------------|--|
| Remarks | Expert statement. The molecular structure of the test substance suggests that it is unlikely |
| | to have oxidising properties. |
| Test Facility | SafePharm (2007c) |

Not oxidising

APPENDIX B: TOXICOLOGICAL INVESTIGATIONS

B.1. Acute toxicity – oral

| TEST SUBSTANCE | Notified chemical |
|---|--|
| Method | OECD TG 420 Acute Oral Toxicity – Fixed Dose Method. EC Directive 2004/73/EC B.1 bis Acute Oral Toxicity – Fixed Dose Procedure. |
| Species/Strain Vehicle Remarks - Method | Rat/Sprague-Dawley CD (Crl:CD(SD)IGS BR) Distilled water No significant protocol deviations. |

RESULTS

| | Dose mg/kg bw | Number and Sex of Animals | Mortality |
|---------------------------|------------------|---|--|
| | 2000 | 5F | 0 |
| LD50 Signs of Toxicity | | >2000 mg/kg bw There were no signs of systemic to in three animals 3 to 5 days after do | exicity. Black stained urine was noted sing. |
| CONCLUSION | | The notified chemical is of low toxi | city via the oral route. |
| TEST FACILITY | | Safepharm (2007e) | |

B.2. Acute toxicity – dermal

| TEST SUBSTANCE | Notified chemical |
|------------------|---|
| Method | OECD TG 402 Acute Dermal Toxicity – Limit Test. EC Directive 92/69/EEC B.3 Acute Toxicity (Dermal) – Limit Test. |
| Species/Strain | Rat/ Sprague-Dawley CD (Crl:CD(SD)IGS BR) |
| Vehicle | Moistened with arachis oil BP |
| Type of dressing | Semi-occlusive. |
| Remarks - Method | No significant protocol deviations. |

RESULTS

| | Dose | Number and Sex | Mortality | |
|--|------------|----------------------------|-----------|--|
| | mg/kg bw | of Animals | | |
| | 2000 | 5M | 0 | |
| | 2000 | 5F | 0 | |
| LD50 | | >2000 mg/kg bw | | |
| Signs of Toxicity - LocalThere were no signs of dermal irritation. | | tion. | | |
| CONCLUSION The notified chemical is of low toxicity via the dermal | | city via the dermal route. | | |
| TEST FACILITY | | Safepharm (2008b) | | |
| | | | | |
| B.3. Irritati | ion — skin | | | |

B.3. Irritation – sl

| TEST SUBSTANCE | |
|----------------|--|
|----------------|--|

Notified chemical

| METHOD Species/Strain Number of Animals Vehicle Observation Period Type of Dressing Remarks - Method RESULTS | OECD TG 404 Acute Dermal Irritation/Corrosion. EC Directive 2004/73/EC B.4 Acute Toxicity (Skin Irritation). Rabbit/New Zealand White 3 Moistened with distilled water 72 hr Semi-occlusive. No significant protocol deviations. |
|---|---|
| Remarks - Results | No evidence of skin irritation was noted in any of the test animals throughout the study. Purple-coloured staining was observed at all treated skin sites during the study. This did not affect evaluation of the skin reactions. |
| Conclusion | The notified chemical is non-irritating to the skin. |
| TEST FACILITY | Safepharm (2007f) |
| B.4. Irritation – eye | Notified chemical |
| TEST SUBSTANCE | Notified chemical |
| METHOD Species/Strain Number of Animals Observation Period Remarks - Method | OECD TG 405 Acute Eye Irritation/Corrosion. EC Directive 2004/73/EC B.5 Acute Toxicity (Eye Irritation). Rabbit/New Zealand White 3 72 hr No significant protocol deviations. |

RESULTS

| Lesion | - | an Sco 1imal N | - | Maximum Value | Maximum Duration of Any Effect | Maximum Value at End of Observation Period |
|------------------------|-----|-------------------|-----|------------------|--------------------------------------|---|
| | 1 | 2 | 3 | | | |
| Conjunctiva: redness | 0.7 | 0.3 | 0.3 | 2 | <72 hr | 0 |
| Conjunctiva: chemosis | 0.3 | 0.3 | 0.3 | 1 | <48 hr | 0 |
| Conjunctiva: discharge | 0.3 | 0.3 | 0.3 | 2 | <48 hr | 0 |
| Corneal opacity | 0 | 0 | 0 | 0 | - | 0 |
| Iridial inflammation | 0 | 0 | 0 | 0 | - | 0 |

The notified chemical is slightly irritating to the eye.

*Calculated on the basis of the scores at 24, 48, and 72 hours for EACH animal.

| CONCLUSION | |
|------------|--|
| | |

TEST FACILITY

Safepharm (2007g)

B.5. Skin sensitisation – mouse local lymph node assay (LLNA)

| TEST SUBSTANCE | Notified chemical |
|----------------|--|
| Method | OECD TG 429 Skin Sensitisation: Local Lymph Node Assay. EC Directive 2004/73/EC B.42 Skin Sensitisation (Local Lymph Node Assay). |
| Species/Strain | Mouse CBA/Ca (CBA/CaBkl) strain |

Vehicle

Remarks - Method

1% pluronic L92 in distilled water No significant protocol deviations. The test substance was not suitable for dosing in any of the solvents recommended in the OECD test guideline. A suitable vehicle and concentration were found with 25% test substance in 1% pluronic L92 in distilled water.

RESULTS

| Concentration | Proliferative response | Stimulation Index |
|---------------------|------------------------|----------------------|
| (% w/w) | (DPM/lymph node) | (Test/Control Ratio) |
| Test Substance | | |
| 0 (vehicle control) | 641.31 | 1.0 |
| 5 | 594.33 | 0.93 |
| 10 | 455.42 | 0.71 |
| 25 | 477.11 | 0.74 |
| Positive Control* | | |
| 1 | Not reported | 1.39 |
| 10 | Not reported | 11.33 |
| 20 | Not reported | 19.34 |

* 2,4-Dinitrobenzenesulfonic acid, sodium salt

CONCLUSION

There was no evidence of induction of a lymphocyte proliferative response indicative of skin sensitisation to the notified chemical.

TEST FACILITY

B.6. Repeat dose toxicity

| TEST SUBSTANCE | Notified chemical |
|-------------------------|--|
| Method | OECD TG 407 Repeated Dose 28-day Oral Toxicity Study in Rodents. EC Directive 96/54/EC B.7 Repeated Dose (28 Days) Toxicity (Oral). |
| Species/Strain | Rat/Sprague-Dawley Crl:CD(SD) IGS BR |
| Route of Administration | Oral – gavage |
| Exposure Information | Total exposure days: 28 days |
| | Dose regimen: 7 days per week |
| | Post-exposure observation period: 14 days |
| Vehicle | Distilled water |
| Remarks - Method | Doses were corrected to account for the 93.3% purity of the test substance. |

Safepharm (2007h)

RESULTS

| Group | Number and Sex of Animals | Dose mg/kg bw/day | Mortality |
|--------------------|------------------------------|----------------------|-----------|
| control | 5M, 5F | 0 | 0 |
| low dose | 5M, 5F | 25 | 0 |
| mid dose 1 | 5M, 5F | 150 | 0 |
| mid dose 2 | 5M, 5F | 300 | 0 |
| high dose | 5M, 5F | 1000 | 0 |
| control recovery | 5M, 5F | 0 | 0 |
| high dose recovery | 5M, 5F | 1000 | 0 |

Mortality and Time to Death

There were no unscheduled deaths.

Clinical Observations

There were isolated observations of fur staining, increased salivation, noisy respiration, and

chromodacryorrhea during the study, mainly in male animals. These were not considered to be of toxicological significance. There were no other toxicologically relevant clinical effects observed.

Laboratory Findings – Clinical Chemistry, Haematology, Urinalysis

There were some statistically significant and dose related changes in a few blood chemistry parameters. These were not considered to be of toxicological relevance given that the mean values were within the historical control ranges.

Several animals from all dose groups (except for controls and recovery groups) showed brown/purple coloured urine. This was considered to be a result of administration of the coloured test substance and not to be of toxicological significance.

Effects in Organs

There were statistically significant changes in the absolute and relative adrenal weights of males and liver weights of females in the high dose recovery group. Considering that such effects were not observed in the non-recovery high dose group, this was not considered to be a biologically significant effect.

High dose females displayed decreased absolute and relative heart weights. Given that there was not a dose related trend in the heart weights, there was no histopathological correlates and that the values were within historical controls, such effects were not considered to be of toxicological significance.

Blue-coloured contents were observed in the gastrointestinal tract and discolouration in the kidneys, lungs and testes of several animals in the mid and high dose groups (mainly male animals). Such effects were believed to be attributed to oral administration of the coloured test substance and were not considered to be toxicologically relevant.

CONCLUSION

The No Observed Effect Level (NOEL) was established as 1000 mg/kg bw/day in this study, based on the absence of toxicologically significant changes in the parameters measured at all dose levels.

TEST FACILITY

Safepharm (2008c)

B.7. Genotoxicity – bacteria

| TEST SUBSTANCE | Notified chemical | |
|--|--|---|
| Method | OECD TG 471 Bacterial Reverse | Mutation Test. |
| | EC Directive 2000/32/EC B.13/14 using Bacteria. | Mutagenicity – Reverse Mutation Test |
| | Plate incorporation procedure | |
| Species/Strain S. typhimurium: TA1535, TA1537, TA98, TA100 | | , TA98, TA100 |
| - | <i>E. coli</i> : WP2uvrA | |
| Metabolic Activation System | S9 fraction from phenobarbitone β | -naphthoflavone-induced rat liver. |
| Concentration Range in | a) With metabolic activation: | 50-5000 μg/plate |
| Main Test | b) Without metabolic activation: | 50-5000 µg/plate |
| Vehicle | Distilled water | |
| Remarks - Method | Formulated concentrations were a test substance. | adjusted to allow for the purity of the |
| | No significant protocol deviations. | |

| Metabolic | Te | st Substance Concentration | bstance Concentration (µg/plate) Resulting in: | | |
|--|--|---|--|--------------------------------|--|
| Activation | Cytotoxicity in Preliminary Test | Cytotoxicity in Main Test | Precipitation | Genotoxic Effect | |
| Absent Test 1 Test 2 | > 5000 | > 5000 > 5000 | > 5000 > 5000 | Negative Negative | |
| Present Test 1 | > 5000 | ≥ 1500 in TA1535 and TA1537 > 5000 other | > 5000 | Negative | |
| Test 2 | | strains > 5000 | > 5000 | Negative | |
| CONCLUSION | | notified chemical was not e test. | mutagenic to bacter | ia under the condition | |
| TEST FACILITY | Safej | pharm (2007i) | | | |
| B.8. Genotoxicity – | bacteria | | | | |
| TEST SUBSTANCE | Notif | fied chemical | | | |
| Method | EC L using Pre i Test Test | D TG 471 Bacterial Reve Directive 2000/32/EC B.13 Bacteria. ncubation procedure 1 of the study utilised the 2 of the study incorporate compounds (Prival ML and | 3/14 Mutagenicity – 1 standard Ames meth ed the Prival and Mit | od. tchell modification for | |
| Species/Strain | Test S. typ E. co Test | azo compounds (Prival MJ and Mitchell VD 1982). Test 1: <i>S. typhimurium</i> : TA1535, TA1537, TA98, TA100 <i>E. coli</i> : WP2uvrA/pKM101 Test 2: | | | |
| Metabolic Activatio | n System Test S9-m Test Ham | nix (details not given) 2: ster liver homogenate m | netabolising system. | Hamster S9 was no | |
| Concentration Rang Main Test Vehicle Remarks - Method | e in a) W b) W Wate Study whet | ed with any enzyme induc ith metabolic activation: ithout metabolic activatio er y summary was provide her all of the appropriate od were performed. | 19.5 - 5000 μg/ n: 19.5 - 5000 μg/ ed. As such, it coul | plate ld not be determined | |

RESULTS

RESULTS

| Metabolic | Tes | st Substance Concentration | 1 (µg/plate) Resultin | g in: |
|------------|------------------|--|-----------------------|----------|
| Activation | Cytotoxicity in | Cytotoxicity in Cytotoxicity in Main Precipitation Genotoxic | | |
| | Preliminary Test | Test | - | |
| Absent | | | | |
| Test 1 | >5000 | >5000 | >5000 | Negative |
| Present | | | | |

| Test 1 | >5000 | >5000 | >5000 | Negative |
|--------------------------|---------------------------------------|--|--|---|
| Test 2 | >5000 | >5000 | >5000 | Negative |
| Remarks - Results | The Pr the tes TA100 sensiti | rival-Mitchell modificat st induced marked incr) revertant colony wi vity of the assay and the x was validated. | ion positive control, T reases in the frequen th metabolic activat | Frypan Blue, used in cy of the TA98 and ion only. Thus, the |
| Conclusion | The no of the | otified chemical was not test. | mutagenic to bacteria | under the conditions |
| TEST FACILITY | Canon | (2007) | | |
| B.9. Genotoxicity – in v | itro | | | |
| TEST SUBSTANCE | Notifie | ed chemical | | |
| Method | EC D Chrom | TG 473 In vitro Mamm irective 2000/32/EC E iosome Aberration Test. | B.10 Mutagenicity - | |
| Species/Strain | | se hamster | T) 11 | |
| Cell Type/Cell Line | | se hamster lung (CHL/IU | | |
| Metabolic Activation S | • | ver S9-mix induced l oflavone | by a combination o | f phenobarbitone/ β - |
| Vehicle | | s Minimal Essential Med | | |
| Remarks - Method | | urity of the test substan gnificant protocol deviati | | in the formulations. |

| Metabolic Activation | Test Substance Concentration (µg/mL) | Exposure Period | Harvest Time |
|-------------------------|--|--------------------|-----------------|
| Absent | | | |
| Test 1 | 0*, 156.25, 312.5, 625, 1250*, 2500*, 5000* | 6 | 24 |
| Test 2 | 0*, 19.5, 39, 78.13*, 156.25*, 234.38*, 312.5* | 24 | 24 |
| Present | | | |
| Test 1 | 0*, 156.25, 312.5, 625*, 1250*, 2500*, 5000* | 6 | 24 |
| Test 2 | 0*, 156.25, 312.5, 625, 1250*, 2500*, 5000* | 6 | 24 |
| | 0*, 156.25, 312.5, 625, 1250*, 2500*, 5000* | 6 | |

RESULTS

| Metabolic | <i>Test Substance Concentration (µg/mL) Resulting in:</i> | | | g in: |
|------------|---|-----------------|---------------|------------------|
| Activation | Cytotoxicity in | Cytotoxicity in | Precipitation | Genotoxic Effect |
| | Preliminary Test | Main Test | | |
| Absent | | | | |
| Test 1 | >2500 | >5000 | >5000 | Negative |
| Test 2 | >5000 | >5000 | >5000 | Negative |
| Present | | | | |
| Test 1 | >5000 | >1250 | >5000 | Negative |
| Test 2 | | >5000 | >5000 | Negative |

Remarks - Results

The test material induced toxicity to CHL cells in all exposure groups, as indicated by the elevated mitotic index values which were considered to be due to toxicity induced cell cycle delay.

The test material did not induce any statistically significant increases in the frequency of cells with aberrations or the number of polyploid cells in any of the exposure groups. CONCLUSIONThe notified chemical was not clastogenic to Chinese hamster lung cells
treated in vitro under the conditions of the test.TEST FACILITYSafepharm (2007j)

APPENDIX C: ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS

C.1. **Environmental Fate**

C.1.1. Ready biodegradability

| TEST SUBSTANCE | Notified chemical |
|-----------------------|---|
| Method | OECD TG 301 C Ready Biodegradability: Modified MITI Test (I). |
| Inoculum | Activated sludge |
| Exposure Period | 28 days |
| Auxiliary Solvent | None |
| Analytical Monitoring | BOD, TOC and HPLC. The results tabulated below reflect BOD determination. |
| Remarks - Method | The notified chemical was tested at 100 mg/L. |

RESULTS

| Test substance | | Aniline | | |
|------------------------------|---|--|---|--|
| Day | % Degradation | Day | % Degradation | |
| 7 | -0.7 | 7 | 57 | |
| 14 | -0.7 | 14 | 71 | |
| 21 | 0.3 | 21 | 73 | |
| 28 | 0.7 | 28 | 74 | |
| Remarks - Results | The test substance HPLC. | The test substance did not undergo any degradation as determined HPLC. | | |
| Conclusion | The notified chemica | The notified chemical is not readily biodegradable. | | |
| TEST FACILITY | Kurume (2007) | Kurume (2007) | | |
| C.1.2. Bioaccumulation | | | | |
| Remarks | Bioaccumulation was not tested. The notified chemical is not expected bioconcentrate in fish because of its high molecular weight and h water solubility. | | | |
| C.2. Ecotoxicologica | al Investigations | | | |
| C.2.1. Acute toxicity to fis | sh | | | |
| TEST SUBSTANCE | Notified chemical | | | |
| Method | | Acute Toxicity Test – EEC C.1 Acute Toxicity | semi-static. y for Fish – semi-static. | |
| Species | Rainbow trout (Onco | - | , | |
| Exposure Period | 96 hours | , | | |
| Auxiliary Solvent | None | | | |
| Water Hardness | 140 mg CaCO ₃ /L | | | |
| A 1 (* 13.6 */ * | | | | |

Spectrophotometry

The limit of quantitation was 0.88 mg/L.

Remarks – Method RESULTS

Water Hardness Analytical Monitoring

| Concentration mg/L | | Number of Fish | | İ | Mortalit | v | |
|-----------------------------|--------------|--|----------|------|----------|------|-----------------|
| Nominal | Actual | | 1 h | 24 h | 48 h | 72 h | 96 h |
| 0 | < 0.88 mg/L | 7 | 0 | 0 | 0 | 0 | 0 |
| 100 | 93.9 | 7 | 0 | 0 | 0 | 0 | 0 |
| 100 | 93.3 | 7 | 0 | 0 | 0 | 0 | 0 |
| LC50 NOEC Remarks – R | esults | > 100 mg/L at 96 hours. 100 mg/L at 96 hours. Results are expressed as nomi concentrations were close to nominal sublethal effects were observed. | | | | | isured 1. No |
| CONCLUSION | | The notified chemical is not harmful | to fish. | | | | |
| TEST FACILITY | | SafePharm (2008d) | | | | | |

C.2.2. Acute toxicity to aquatic invertebrates

| TEST SUBSTANCE | Notified chemical |
|-----------------------|---|
| Method | OECD TG 202 Daphnia sp. Acute Immobilisation Test and Reproduction Test - static. EC Directive 92/69/EEC C.2 Acute Toxicity for Daphnia - static. |
| Species | Daphnia magna |
| Exposure Period | 48 hours |
| Auxiliary Solvent | None |
| Water Hardness | 140 mg CaCO ₃ /L |
| Analytical Monitoring | Spectrophotometry |
| Remarks - Method | The limit of quantitation was 0.88 mg/L. |

RESULTS

| Concentre | ation mg/L | Number of D. magna Number Immo | | nmobilised |
|------------------------------|------------|--|---------------------|------------------|
| Nominal | Actual | | 24 h | 48 h |
| 0 | < 0.88 | 20 | 0 | 0 |
| 100 | 94.5-96.5 | 20 | 0 | 0 |
| EC50 NOEC Remarks - Re | sults | > 100 mg/L at 48 hours 100 mg/L at 48 hours The response to the positive contro the normal range. | l (potassium dichro | mate) was within |
| CONCLUSION | | The notified chemical is not harmful | to daphnids | |
| TEST FACILITY | | SafePharm (2008e) | | |

C.2.3. Algal growth inhibition test

| TEST SUBSTANCE | Notified chemical |
|---------------------|--|
| Method | OECD TG 201 Alga, Growth Inhibition Test. EC Directive 92/69/EEC C.3 Algal Inhibition Test. |
| Species | Desmodesmus subspicatus |
| Exposure Period | 72 hours |
| Concentration Range | Nominal: 0.1, 1, 10, 100 mg/L |
| Auxiliary Solvent | None |
| Water Hardness | Typical algal culture medium (soft water) |

| Analytical Monitoring | Not conducted |
|-----------------------|---|
| Remarks - Method | A range finding study only was conducted, because significant light |
| | absorption by the test substance was measured at 460 and 665 nm. |

RESULTS

| Yield | | Growth | | |
|-------------------|-------------------|---|------|--|
| E_yC50 | NOEC | E_rC50 | NOEC | |
| mg/L at 72 h | mg/L | mg/L at 72 h | mg/L | |
| ~ 10 | Not determinable | > 100 | 1 | |
| Remarks - Results | 1 0 | bition of growth rate (8, 5, tration. Corresponding value | , | |
| CONCLUSION | | ical is not harmful to the colour and consequent re ynthesis. | | |
| TEST FACILITY | SafePharm (2008f) | | | |

C.2.4. Lemna growth inhibition test

| TEST SUBSTANCE | Notified chemical |
|-----------------------|---|
| METHOD | OECD TG 221 Lemna sp. Growth Inhibition Test. |
| Species | Lemna minor |
| Exposure Period | 7 days |
| Concentration Range | Nominal: 0.1, 1, 10, 100 mg/L |
| Auxiliary Solvent | None |
| Analytical Monitoring | Spectrophotometry (LOQ 0.88 mg/L) |
| Remarks – Method | Test solutions were renewed on days 2 and 5. |

RESULTS

| Yiel | d | Grow | vth |
|--------------|------|--------------|------|
| $E_{y}C50$ | NOEC | E_rC50 | NOEC |
| mg/L at 72 h | mg/L | mg/L at 72 h | mg/L |
| > 100 | 100 | > 100 | 100 |

| Remarks - Results | The response to the positive control $(3,5$ -dichlorophenol) was within the normal range. There was some dark colouration observed at the highest test concentration of 100 mg/L notified chemical. Nominal concentrations of the notified chemical were confirmed by analysis. |
|-------------------|---|
| Conclusion | The notified chemical is not harmful to duckweed. |
| TEST FACILITY | SafePharm (2008g) |

C.2.5. Inhibition of microbial activity

| TEST SUBSTANCE | Notified chemical |
|----------------|--|
| Method | OECD TG 209 Activated Sludge, Respiration Inhibition Test. EC Directive 88/302/EEC C.11 Biodegradation: Activated Sludge Respiration Inhibition Test |
| Inoculum | Activated sludge from the aeration stage of the Severn Trent Water Plc |

| Exposure Period Concentration Range Remarks – Method | sewage treatment plant which treats predominantly domestic sewage. 3 hours Nominal: 1, 10, 100, 1000 mg/L 3,5-Dichlorophenol was used as reference material. |
|--|---|
| RESULTS IC50 NOEC Remarks – Results | > 1000 mg/L 1000 mg/L The IC50 for the reference substance was 16 mg/L |
| CONCLUSION | The notified chemical is not harmful to the respiration of sewage sludge microorganisms. |
| TEST FACILITY | SafePharm (2008h) |

BIBLIOGRAPHY

- Brown MA and DeVito SC (1993). Predicting Azo Dye Toxicity. *Critical Reviews in Environmental Science* and Technology. 23(3):249-324.
- Canon (2007) A reverse mutation test of C-BK4 using bacteria, Prival and Mitchell modification for azo compounds. Experiment no 06-467, January 2007. Canon Inc, Quality Management Headquarters, Kanagawa, Japan. (unpublished report provided by notifier).
- EC (2004) EC Directive 76/769/EEC, Office for Official Publications of the European Communities http://europa.eu.int/comm/enterprise/chemicals/legislation/markrestr/consolid_1976L0769_en.pdf
- European Commission (2003) Technical Guidance Document on Risk Assessment in Support of Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances and Commission Regulation (EC) No 1488/94 on Risk Assessment for Existing Substances and Directive 98/8/EC of the European Parliament and of the Council Concerning the Placing of Biocidal Products on the Market – Part I. Institute for Health and Consumer protection, European Chemicals Bureau, European Communities.
- Kurume (2007) Biodegradation study of C-BK4 by microorganisms. Study no 14894, September 2007. Kurume Laboratory, Chemicals Evaluation and Research Institute, Japan. (unpublished report provided by notifier).
- NOHSC (1994) National Code of Practice for the Labelling of Workplace Substances [NOHSC:2012(1994)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2003) National Code of Practice for the Preparation of Material Safety Data Sheets, 2nd edition [NOHSC:2011(2003)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2004) Approved Criteria for Classifying Hazardous Substances, 3rd edition [NOHSC:1008(2004)]. National Occupational Health and Safety Commission, Canberra, AusInfo.
- Øllgaard H, Frost L, Galster J and Hansen OC (1998). Survey of azo-colorants in Denmark: Consumption, use, health and environmental aspects. Danish Technological Institute, Environment, Danish Environmental Protection Agency.
- Prival MJ and Mitchell VD (1982) Analysis of a method for testing azo dyes for mutagenic activity in *Salmonella typhimurium* in the presence of flavin mononucleotide and hamster liver S9. *Mutat Res.* 97(2): 103-16.
- SafePharm (2007a) C-BK4: Determination of melting/freezing temperature, boiling temperature, water solubility and partition coefficient. Project no 0345/0861, June 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007b) C-BK4: Determination of general physico-chemical properties. Project no 0345/0918, July 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007c) C-BK4: Determination of hazardous physico-chemical properties. Project no 0345/0919, June 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007d) C-BK4: Determination of flammability (solids). Project no 0345/0862, April 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007e) C-BK4: Acute oral toxicity in the rat fixed dose method. Project no 0345/0863, May 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007f) C-BK4: Acute dermal irritation in the rabbit. Project no 0345/0864, May 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007g) C-BK4: Acute eye irritation in the rabbit. Project no 0345/0865, May 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007h) C-BK4: Local lymph node assay in the mouse. Project no 0345/0866, June 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2007i) C-BK4: Reverse mutation assay "Ames test" using *Salmonella Typhimurium* and *Escherichia coli*. Project no 0345/0868, July 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).

- SafePharm (2007j) C-BK4: Chromosome aberration test in CHL cells in vitro. Project no 0345/0867, September 2007. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008a) C-BK4: Determination of surface tension. Project no 0345/0990, March 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008b) C-BK4: Acute dermal toxicity (limit test) in the rat. Project no 0345/0991, May 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008c) C-BK4: Twenty-eight day repeated dose oral (gavage) toxicity study in the rat. Project no 0345/0992, September 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008d) C-BK4: Acute toxicity to rainbow trout (*Oncorhynchus mykiss*). Project no 0345/0993, May 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008e) C-BK4: Acute toxicity to *Daphnia magna*. Project no 0345/0994, May 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008f) C-BK4: Algal growth inhibition test. Project no 0345/0995, May 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008g) C-BK4: *Lemna minor* growth inhibition test. Project no 0345/0995, August 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SafePharm (2008h) C-BK4: Assessment of the inhibitory effect on the respiration of activated sewage sludge. Project no 0345/0996, April 2008. SafePharm Laboratories, Derbyshire, UK. (unpublished report provided by notifier).
- SCCNFP (2002) The Safety Review Of The Use Of Certain Azo-Dyes In Cosmetic Products: Opinion Of The Scientific Committee On Cosmetic Products And Non-Food Products Intended For Consumers.. SCCNFP/0495/01 (prepared in the context of Directive 76/768/EEC).